Response to expression of concern regarding VIGOR study.
Claire
C
Bombardier
Loren
L
Laine
Ruben
R
Burgos-Vargas
Barry
B
Davis
Richard
R
Day
Marcos Bosi
MB
Ferraz
Christopher J
CJ
Hawkey
Marc C
MC
Hochberg
Tore K
TK
Kvien
Thomas J
TJ
Schnitzer
Arthur
A
Weaver
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology* / Q000401:mortality; D003627:Data Interpretation, Statistical; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000139:chemically induced*; D009288:Naproxen / Q000009:adverse effects* / Q000627:therapeutic use; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use
D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D009288:Naproxen